Although ALK inhibitors are effective in most patients with EML4-ALK positive NSCLC, the eventual development of acquired resistance remains a major concern in the treatment of EML4-ALK translocated lung adenocarcinomas. Here, EML4 is linked to lung adenocarcinoma.